Effect of sardine proteins on hyperglycaemia, hyperlipidaemia and lecithin: cholesterol acyltransferase activity, in high-fat diet-induced type 2 diabetic rats

Nora Benaicheta, Fatima Z. Labbaci, Malika Bouchenak and Farida O. Boukortt*

Laboratoire de Nutrition Clinique et Métabolique, Faculté des Sciences de la Nature et de la Vie, Université d’Oran 1 Ahmed Ben Bella, BP 1524 El M’Naouer, 31000 Oran, Algérie

(Submitted 31 July 2015 – Final revision received 20 September 2015 – Accepted 23 September 2015 – First published online 28 October 2015)

Abstract
Type 2 diabetes (T2D) is a major risk factor of CVD. The effects of purified sardine proteins (SP) were examined on glycaemia, insulin sensitivity and reverse cholesterol transport in T2D rats. Rats fed a high-fat diet (HFD) for 5 weeks, and injected with a low dose of streptozotocin, were used. The diabetic rats were divided into four groups, and they were fed casein (CAS) or SP combined with 30 or 5 % lipids, for 4 weeks. HFD-induced hyperglycaemia, insulin resistance and dyslipidaemia in rats fed HFD, regardless of the consumed protein. In contrast, these parameters lowered in rats fed SP combined with 5 or 30 % lipids, and serum insulin values reduced in SP v. CAS. HFD significantly increased total cholesterol and TAG concentrations in the liver and serum, whereas these parameters decreased with SP, regardless of lipid intake. Faecal cholesterol excretion was higher with SP v. CAS, combined with 30 or 5 % lipids. Lecithin:cholesterol acyltransferase (LCAT) activity and HDL2-cholesteryl esters (CE) were lower. Otherwise, LCAT activity and HDL2-CE were higher in the SP group than in the CAS group, whereas HDL3-PL and HDL3-unesterified cholesterol were lower. Moreover, LCAT activity lowered in the SP-HF group than in the CAS-HF group, when HDL2-CE was higher. In conclusion, these results indicate the potential effects of SP to improve glycaemia, insulin sensitivity and reverse cholesterol transport, in T2D rats.

Key words: Rats: High-fat diets: Hyperglycaemia: Dyslipidaemia: Lecithin:cholesterol acyltransferase

Type 2 diabetes (T2D) is a complex, heterogeneous and polygenic disease characterised mainly by insulin resistance and pancreatic β-cell dysfunction\(^{(1)}\). Impaired postprandial insulin secretion, because of functional defects and loss of pancreatic β-cells, leads to hyperglycaemia and subsequent decline in insulin sensitivity\(^{(2)}\). Hyperglycaemia and hyperlipidaemia that accompanied T2D are key promoters of dysmetabolism\(^{(3)}\).

Relationships between diabetes and diet composition have been shown in several humans and animals studies. Data reported that the type of fats in the diet may affect insulin resistance in animals\(^{(4)}\). Rodents fed a high-fat diet (HFD) developed impaired intracellular glucose metabolism within 4 weeks. These animals also showed visceral obesity, whole-body and skeletal muscle insulin resistance, hyperinsulinaemia, hyperglycaemia and hyperlipidaemia\(^{(5)}\).

In recent years, much focus has been placed on the beneficial effects of fish consumption, which many of positive effects on dyslipidaemia and heart diseases have been attributed to \(n-3\) PUFA contained in fish oils\(^{(6)}\). However, authors have previously demonstrated that protein component may also have an important role in the beneficial effects of fish consumption\(^{(7,8)}\). In this case, Lavigne et al.\(^{(9)}\) have reported that cod protein in a high-fat, high-sucrose diet protected against the development of obesity-linked insulin resistance and glucose intolerance in rats, and it improved insulin sensitivity in insulin-resistant individuals\(^{(8)}\). Moreover, a recent study showed that HFD combined with various fish proteins had anti-inflammatory effects and that salmon proteins protected against visceral obesity\(^{(10)}\). Data have reported the importance of fish protein in the regulation of cholesterol metabolism\(^{(11)}\). Moreover, studies have demonstrated the beneficial effect of sardine proteins (SP) on hyperglycaemia and hyperlipidaemia in streptozotocin (STZ)-induced diabetic rats\(^{(12)}\).

The aim of this study was to investigate the effects of SP on glycaemia, insulin resistance and reverse cholesterol transport, in T2D rats induced with an HFD (30 % lipids), associated with STZ injection.

Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BW, body weight; CAS, casein; CE, cholesteryl esters; HbA1c, glycosylated Hb; HFD, high-fat diet; HOMA-IR, homeostasis model assessment insulin resistance; LCAT, lecithin:cholesterol acyltransferase; PL, phospholipids; SP, sardine proteins; STZ, streptozotocin; TC, total cholesterol; UC, unesterified cholesterol.

* Corresponding author: F. O. Boukortt, fax +213 554 25 64 96, email faridadboukortt@gmail.com
Methods

Preparation of sardine proteins

Fish proteins isolated from sardine (Sardina pilchardus) fillets were previously described by Mellok et al. Purified SP preparation constituted 92% proteins, 0-2% lipids and 4-8% ashes.

Animals and diets

Male Wistar rats (n 30) (Pasteur Institute) weighing 260 (SEM 25) g were maintained at stable temperature (22–23°C) and humidity (60%), with 12 h light–12 h dark cycle (light 07:00–19:00 hours). This study was approved by our Institutional Animal Research Committee. The General Guidelines on the Use of Living Animals in Scientific Investigations Council of European Communities (1987) were followed

At the beginning of the experiment, rats were fed an HFD containing 20% casein (CAS) and 30% butter (containing 67% sunflower oil, 9% olive, 1% nut, 0% fish) (kits; Chronolab) and after 48 h STZ injection 24 h later 28 d were studied. Rats weighing 366 (SEM 25) kg received a single intra-peritoneal injection of low-dose STZ (35 mg/kg body weight (BW)) (Sigma) in 0.9% NaCl 0.5% (5 ml/kg BW). Blood was withdrawn immediately, rinsed with cold NaCl 0.9% solution and fasted for 24 h before insulin resistance index was estimated by the homeostasis model assessment (HOMA-IR) was calculated using relationships between blood glucose and insulin levels, according to formula: HOMA-IR index = (fasting glucose (mmol/l) – fasting insulin (μU/ml))/22.3.

Blood and liver samples

At d28, after overnight food deprivation, rats were anesthetised with pentobarbital 10% (3 mg/kg BW). Blood was withdrawn immediately, rinsed with cold NaCl 0.9%, dried and weighed. An aliquot of 100 mg of liver was stored at −70°C until analysis.

Biochemical analysis

The calculation of intra- and inter-assay imprecision (%CV) in the followed assays was between 10 and 15%. In our experiment, for the insulin and serum glucose, the results showed a low variability of the data, indicating an homogeneous data, whereas for lecithin:cholesterol acyltransferase (LCAT) activity, particularly for SP and SP-HF groups, the %CV exceeds 15%, reflecting a wide variability between the animals (heterogeneous data).

Serum glucose, insulin and glycosylated Hb

Serum glucose concentration was measured using a glucose oxidase (kit; Spinreact). Taking into account the variability of serum glucose levels in rats, glycosylated Hb (HbA1c) levels were used as an index of glucose control. HbA1c was measured by the cation-exchange resin (micro-column) method (kit; BioSystems). Serum insulin levels (kit; SPL-Bio) were determined and insulin resistance index estimated by the homeostasis model assessment (HOMA-IR) was calculated using relationships between blood glucose and insulin levels, according to formula: HOMA-IR index = (fasting glucose (mmol/l) – fasting insulin (μU/ml))/22.3. HOMA-β, which estimates the β-cell function rate, was calculated using the following equation: (20 × fasting insulin (μU/ml)/(fasting glucose (mmol/l) – 3.5))°°°

Transaminases

Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) activities, used as biochemical markers for hepatic damage, were determined using enzymatic methods (kits; Chronolab).

Lipoprotein separation

Serum VLDL and LDL-HDL₃ were isolated by precipitation using the MgCl₂/phosphotungstate method. HDL₄ and HDL₃ subfractions were separated by the precipitation method, using dextran sulphate and MgCl₂ (Sigma Chemical Company).

Lipid parameters

Liver total lipids were determined by the method of Delsal. TAG and total cholesterol (TC) were determined in serum, liver and lipoprotein fractions by enzymatic methods (kits; Biocon Diagnostik). Phospholipids (PL) were determined by the enzymatic method (kit; Cypress Diagnostics).

Table 1. Composition of the experimental diet (g/kg)

<table>
<thead>
<tr>
<th>Compounds</th>
<th>CAS (g)</th>
<th>SP (g)</th>
<th>CAS-HF (g)</th>
<th>SP-HF (g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Energy content (kJ/g diet)</td>
<td>15-94</td>
<td>15-94</td>
<td>21-17</td>
<td>21-17</td>
</tr>
<tr>
<td>CAS (g)</td>
<td>200</td>
<td>–</td>
<td>200</td>
<td>–</td>
</tr>
<tr>
<td>SP (g)</td>
<td>–</td>
<td>200</td>
<td>–</td>
<td>200</td>
</tr>
<tr>
<td>Sucrose (g)</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Maize starch (g)</td>
<td>590</td>
<td>590</td>
<td>340</td>
<td>340</td>
</tr>
<tr>
<td>Cellulose (g)</td>
<td>50</td>
<td>50</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>Vitamin mix (g)</td>
<td>20</td>
<td>20</td>
<td>20</td>
<td>20</td>
</tr>
<tr>
<td>Mineral mix (g)</td>
<td>40</td>
<td>40</td>
<td>40</td>
<td>40</td>
</tr>
<tr>
<td>Lipid mix (g)</td>
<td>50</td>
<td>50</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Butter (g)</td>
<td>–</td>
<td>300</td>
<td>300</td>
<td>300</td>
</tr>
<tr>
<td>Total</td>
<td>1000</td>
<td>1000</td>
<td>1000</td>
<td>1000</td>
</tr>
</tbody>
</table>

CAS, casein; SP, sardine proteins; HF, high fat.

† Prolabo.

† ENASUCRE.

‡ Sidi Bel Abbès.

§ UAR 200: vitamin mixture provides the following amounts (mg/kg diet): retinol, 12; cholecalciferol, 0.125; thiamine, 40; riboflavin, 30; panthothenic acid, 140; pyridoxine, 20; niacin, 300; cyanocobalamin, 0.1; ascorbic acid, 1,600; α-tocopherol, 340; menadione, 80; nicotinic acid, 200; para-aminobenzoic acid, 100; folic acid, 10; biotin, 0.6.

¶ UAR 205 B: the salt mixture provides the following amounts (mg/kg diet): CaHPO₄, 17,200; KCl, 4,000; NaCl, 400; MgO, 420; MgSO₄, 2000; FeCl₃, 120; FeSO₄, 7H₂O, 200; trace elements, 400; MnSO₄, 98; CuSO₄, 7H₂O, 20; ZnSO₄, 80; CoSO₄, 7H₂O, 0.16; KI, 0.32.

‖ Lipid mix: lipid mixture provides the following amounts (g/kg diet): sunflower oil, 10; olive oil, 39; walnut oil, 1 (with n-6:n-3 = 7). Olive and sunflower oils from Cevital; walnut oil from Cauvin.

** Butter, commercial butter from Oran.

Downloaded from https://www.cambridge.org/core. IP address: 54.70.40.11, on 26 Apr 2018 at 17:45:01, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S0007114515004195
Determination of lecithin:cholesterol acyltransferase activity

LCAT activity was determined on fresh serum by the endogenous method\(^{19}\), and it was based on disappearance of unesterified cholesterol (UC) molecules, which were transformed into esterified cholesterol (EC) after 4 h of incubation at 37°C, starting from a fatty acid and lecithin. UC value was determined by the enzymatic method (kit CHOD-PAP; Wako Chemicals). LCAT activity was expressed as nanomoles of EC/h per ml of serum.

Statistical analysis

Results were expressed as means with their standard errors of six rats per group. Statistical analysis of data was determined using STATISTICA 4.1 (StatSoft). Data were tested by two-way ANOVA followed by non-parametric least significant difference test. Differences and effects were considered significant at \(P<0.05\) – protein effect: SP vs. CAS regardless of the lipid content in the diet, and lipids effect: 5 vs. 30 % lipids regardless of the protein.

Results

Body weight, food and water intake, and urine volume

At d0, the BW of the rats was similar in all the groups, whereas, at d28, an increase by 20 % was observed in the SP-HF group compared with the CAS-HF group. In SP, CAS and SP-HF groups, a weight gain was noted, whereas a loss was shown in the CAS-HF group. There was no significant difference in food and water intake (Table 2). Urine volume was increased by 28 % in CAS-HF compared with CAS and decreased by 15 % in SP-HF compared with CAS-HF (Table 2).

Glycaemia

At d7, d14, d21 and d28 of the experiment, glycaemia was increased by 26, 17, 49 and 135 %, respectively, in the CAS-HF group compared with the CAS group (Fig. 1). In contrast, glycaemia was lowered by 22, 26 and 33 % in SP compared with CAS at d14, d21 and d28 of the experiment, and by 23, 37, 43 and 28 % in CAS-HF compared with CAS and decreased by 15 % in SP-HF compared with CAS regardless of the lipid content in the diet. Urine glucose was increased by 35 % in CAS-HF compared with CAS, whereas in SP vs. CAS and SP-HF vs. CAS-HF urine glucose concentrations were reduced by 28 and 40 %, respectively (Table 3).

Serum glucose, insulinaemia, glycosylated Hb, homeostasis model assessment insulin resistance, homeostasis model assessment β, aspartate aminotransferase, alanine aminotransferase activities and urine glucose

The HFD consumption induced an elevation of HOMA-IR, AST and ALT activities regardless of the consumed proteins, whereas HOMA-β index was reduced by 55 % in CAS-HF vs. CAS. In SP vs. CAS, a decrease was observed in serum glucose (64 %), HOMA-IR index (71 %), HbA1c (41 %), AST (17 %) and ALT (38 %) activities. Similarly, in SP-HF vs. CAS-HF, a significant decrease was observed in serum glucose (37 %), HOMA-IR index (51 %), HbA1c (29 %), AST (27 %) and ALT (44 %). Moreover, serum insulin level lowered by 51 % in the SP group compared with the CAS group. In addition, HOMA-β was increased in rats fed SP regardless of the lipid content in the diet. Urine glucose was increased by 35 % in CAS-HF compared with CAS, whereas in SP vs. CAS and SP-HF vs. CAS-HF urine glucose concentrations were reduced by 28 and 40 %, respectively (Table 3).

Serum, liver and faecal lipid concentrations

Serum TC and TAG concentrations were increased, respectively, by 48 and 101 % in CAS-HF vs. CAS and by 32 and 86 % in SP-HF vs. SP. Similarly, high values were noted in liver TC and TAG (76 and 48 %, respectively) in CAS-HF vs. CAS and (30 and 21 %, respectively) in SP-HF vs. SP (Table 4). Interestingly, these

---

**Table 2. Body weight, food and water intake and urine volume**

(Mean values with their standard errors)

<table>
<thead>
<tr>
<th></th>
<th>CAS</th>
<th>SP</th>
<th>CAS-HF</th>
<th>SP-HF</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean ± SEM</td>
<td>Mean ± SEM</td>
<td>Mean ± SEM</td>
<td>Mean ± SEM</td>
</tr>
<tr>
<td>Body weight at d0 (g)</td>
<td>365.66 ± 29.00</td>
<td>366.00 ± 17.00</td>
<td>362.00 ± 33.00</td>
<td>371.16 ± 32.13</td>
</tr>
<tr>
<td>Body weight after 4 weeks (g)</td>
<td>373.16 ± 38.25</td>
<td>382.83 ± 39.32</td>
<td>336.33 ± 21.20</td>
<td>402.50 ± 28.00</td>
</tr>
<tr>
<td>Changes in body weight (g)</td>
<td>+13.40 ± 3.00</td>
<td>+16.00 ± 2.64</td>
<td>-27.00 ± 5.66</td>
<td>+30.25 ± 10.40</td>
</tr>
<tr>
<td>Food intake (g/d per rat)</td>
<td>26.16 ± 4.30</td>
<td>26.44 ± 3.08</td>
<td>24.48 ± 4.95</td>
<td>28.40 ± 2.10</td>
</tr>
<tr>
<td>Water intake (ml/d per rat)</td>
<td>273.60 ± 24.17</td>
<td>280.80 ± 19.25</td>
<td>279.20 ± 17.48</td>
<td>280.60 ± 26.05</td>
</tr>
<tr>
<td>Urine volume (ml/d per rat)</td>
<td>57.66 ± 1.57</td>
<td>60.80 ± 3.68</td>
<td>73.66 ± 2.98</td>
<td>62.40 ± 4.50</td>
</tr>
</tbody>
</table>

CAS, casein; SP, sardine proteins; HF, high fat.

* Statistical analysis was performed using the least significant difference test. The values were significantly different at \(P<0.05\).

† SP vs. CAS (\(P<0.05\)).

‡ SP-HF vs. SP or CAS-HF vs. CAS (\(P<0.05\)).
values decreased in SP compared with CAS, and in SP-HF compared with CAS-HF. Faecal total lipids were 2.08- and 2.22-fold higher, respectively, in SP than in CAS and in SP-HF than in CAS-HF. Indeed, faecal cholesterol concentrations were 1.58- and 1.53-fold higher, respectively, in the same groups.

**Table 3. Serum biochemical parameters**

(Mean values with their standard errors)

<table>
<thead>
<tr>
<th></th>
<th>CAS</th>
<th>SEM</th>
<th>SP</th>
<th>SEM</th>
<th>CAS-HF</th>
<th>SEM</th>
<th>SP-HF</th>
<th>SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum glucose (mM)</td>
<td>21.35</td>
<td>2.83</td>
<td>7.75†</td>
<td>0.41</td>
<td>23.15</td>
<td>1.71</td>
<td>14.49‡</td>
<td>2.07</td>
</tr>
<tr>
<td>Insulin (pmol/l)</td>
<td>292.1</td>
<td>21.91</td>
<td>140.87†</td>
<td>43.82</td>
<td>331.77</td>
<td>24.89</td>
<td>292.10‡</td>
<td>21.91</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>36.88</td>
<td>1.94</td>
<td>10.73†</td>
<td>2.54</td>
<td>50.54‡</td>
<td>4.14</td>
<td>24.90‡</td>
<td>1.50</td>
</tr>
<tr>
<td>HOMA-β</td>
<td>75.27</td>
<td>8.67</td>
<td>86.36†</td>
<td>0.87</td>
<td>34.09‡</td>
<td>1.93</td>
<td>151.14‡</td>
<td>0.14</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>12.41</td>
<td>1.73</td>
<td>7.36†</td>
<td>0.36</td>
<td>11.70</td>
<td>1.51</td>
<td>8.32†</td>
<td>0.24</td>
</tr>
<tr>
<td>AST (U/l)</td>
<td>75.75</td>
<td>2.06</td>
<td>62.89†</td>
<td>4.76</td>
<td>113.33‡</td>
<td>2.02</td>
<td>82.19‡</td>
<td>12.63</td>
</tr>
<tr>
<td>ALT (U/l)</td>
<td>40.69</td>
<td>3.99</td>
<td>25.06†</td>
<td>6.74</td>
<td>77.25‡</td>
<td>5.83</td>
<td>43.19‡</td>
<td>7.64</td>
</tr>
<tr>
<td>Urine glucose (mM)</td>
<td>11.43</td>
<td>0.59</td>
<td>8.24†</td>
<td>0.46</td>
<td>15.46‡</td>
<td>0.14</td>
<td>9.30‡</td>
<td>0.97</td>
</tr>
</tbody>
</table>

CAS, cassein; SP, sardine proteins; HF, high fat; HOMA-IR, homeostasis model assessment insulin resistance; HbA1c, glycosylated Hb; AST, aspartate aminotransferase; ALT, alanine aminotransferase.

*Statistical analysis was performed using the least significant difference test. The values were significantly different at P < 0.05.
† SP v. CAS (P < 0.05).
‡ SP-HF v. SP or CAS-HF v. CAS (P < 0.05).

**Table 4. Serum, liver and faecal lipid concentrations**

(Mean values with their standard errors)

<table>
<thead>
<tr>
<th></th>
<th>CAS</th>
<th>SEM</th>
<th>SP</th>
<th>SEM</th>
<th>CAS-HF</th>
<th>SEM</th>
<th>SP-HF</th>
<th>SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum TC (mM)</td>
<td>3.18</td>
<td>0.37</td>
<td>1.90†</td>
<td>0.12</td>
<td>4.71‡</td>
<td>0.73</td>
<td>2.51‡</td>
<td>0.44</td>
</tr>
<tr>
<td>TAG (mM)</td>
<td>1.75</td>
<td>0.22</td>
<td>1.06†</td>
<td>0.20</td>
<td>3.51‡</td>
<td>0.43</td>
<td>1.97‡</td>
<td>0.58</td>
</tr>
<tr>
<td>Liver TC (μmol/g liver)</td>
<td>17.00</td>
<td>1.05</td>
<td>12.28†</td>
<td>1.25</td>
<td>29.92†</td>
<td>1.21</td>
<td>16.01‡</td>
<td>1.15</td>
</tr>
<tr>
<td>TAG (μmol/g)</td>
<td>24.15</td>
<td>1.55</td>
<td>16.50†</td>
<td>3.70</td>
<td>35.65‡</td>
<td>2.33</td>
<td>19.89‡</td>
<td>1.30</td>
</tr>
<tr>
<td>Faeces Total lipids (mg/d per rat)</td>
<td>86.03</td>
<td>5.23</td>
<td>179.22‡</td>
<td>4.25</td>
<td>73.97</td>
<td>0.91</td>
<td>164.00‡</td>
<td>2.88</td>
</tr>
<tr>
<td>Cholesterol (mg/d per rat)</td>
<td>106.70</td>
<td>5.61</td>
<td>168.60‡</td>
<td>5.39</td>
<td>118.03‡</td>
<td>3.28</td>
<td>180.33‡</td>
<td>5.68</td>
</tr>
</tbody>
</table>

CAS, cassein; SP, sardine proteins; HF, high fat; TC, total cholesterol.

*Statistical analysis was performed using the least significant difference test. The values were significantly different at P < 0.05.
† SP v. CAS (P < 0.05).
‡ SP-HF v. SP or CAS-HF v. CAS (P < 0.05).

**Table 5. Distribution of cholesterol and TAG in lipoproteins**

(Mean values with their standard errors)

<table>
<thead>
<tr>
<th></th>
<th>CAS</th>
<th>SEM</th>
<th>SP</th>
<th>SEM</th>
<th>CAS-HF</th>
<th>SEM</th>
<th>SP-HF</th>
<th>SEM</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cholesterol VLDL (mM)</td>
<td>0.78</td>
<td>0.04</td>
<td>0.33†</td>
<td>0.05</td>
<td>2.13‡</td>
<td>0.10</td>
<td>0.89‡</td>
<td>0.04</td>
</tr>
<tr>
<td>LDL-HDL (mM)</td>
<td>0.65</td>
<td>0.07</td>
<td>0.50†</td>
<td>0.01</td>
<td>0.93‡</td>
<td>0.03</td>
<td>0.58‡</td>
<td>0.07</td>
</tr>
<tr>
<td>HDL2 (mM)</td>
<td>0.60</td>
<td>0.06</td>
<td>0.90†</td>
<td>0.02</td>
<td>0.32‡</td>
<td>0.07</td>
<td>0.25‡</td>
<td>0.01</td>
</tr>
<tr>
<td>HDL3 (mM)</td>
<td>0.64</td>
<td>0.02</td>
<td>0.40†</td>
<td>0.09</td>
<td>0.63</td>
<td>0.11</td>
<td>0.57‡</td>
<td>0.06</td>
</tr>
<tr>
<td>TAG VLDL (mM)</td>
<td>0.85</td>
<td>0.04</td>
<td>0.38†</td>
<td>0.01</td>
<td>1.78‡</td>
<td>0.03</td>
<td>1.25‡</td>
<td>0.01</td>
</tr>
<tr>
<td>LDL-HDL (mM)</td>
<td>0.31</td>
<td>0.03</td>
<td>0.17†</td>
<td>0.03</td>
<td>0.64‡</td>
<td>0.03</td>
<td>0.32‡</td>
<td>0.01</td>
</tr>
<tr>
<td>HDL2 (mM)</td>
<td>0.30</td>
<td>0.01</td>
<td>0.20†</td>
<td>0.02</td>
<td>0.49‡</td>
<td>0.02</td>
<td>0.21‡</td>
<td>0.05</td>
</tr>
<tr>
<td>HDL3 (mM)</td>
<td>0.21</td>
<td>0.05</td>
<td>0.16†</td>
<td>0.03</td>
<td>0.32‡</td>
<td>0.03</td>
<td>0.16‡</td>
<td>0.04</td>
</tr>
</tbody>
</table>

CAS, cassein; SP, sardine proteins; HF, high fat.

*Statistical analysis was performed using the least significant difference test. The values were significantly different at P < 0.05.
† SP v. CAS (P < 0.05).
‡ SP-HF v. SP or CAS-HF v. CAS (P < 0.05).
Table 6. Serum lecithin:cholesterol acyltransferase (LCAT) activity, apoA-I, HDL3-phospholipids (PL), HDL3-unesterified cholesterol (UC), HDL2-cholesteryl esters (CE) and apo-HDL3*.
(Mean values with their standard errors)

<table>
<thead>
<tr>
<th></th>
<th>CAS</th>
<th>SP</th>
<th>CAS-HF</th>
<th>SP-HF</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (nmol/h per ml)</td>
<td>SEM</td>
<td>Mean (nmol/h per ml)</td>
<td>SEM</td>
</tr>
<tr>
<td>LCAT</td>
<td>2.91 0.30</td>
<td>11.60† 2.30</td>
<td>27.55† 2.09</td>
<td>16.74† 5.81</td>
</tr>
<tr>
<td>ApoA-I (g/l)</td>
<td>0.37 0.05</td>
<td>0.70† 0.04</td>
<td>0.37 0.02</td>
<td>0.60† 0.03</td>
</tr>
<tr>
<td>HDL2-PL (mu)</td>
<td>0.54 0.04</td>
<td>0.30† 0.02</td>
<td>0.70† 0.04</td>
<td>0.64† 0.05</td>
</tr>
<tr>
<td>HDL2-UC (mu)</td>
<td>0.29 0.03</td>
<td>0.18† 0.04</td>
<td>0.28 0.06</td>
<td>0.32 0.01</td>
</tr>
<tr>
<td>HDL2-CE (mu)</td>
<td>0.32 0.07</td>
<td>1.01† 0.17</td>
<td>0.09† 0.02</td>
<td>0.16† 0.04</td>
</tr>
<tr>
<td>Apo-HDL3 (g/l)</td>
<td>3.95 0.16</td>
<td>3.98 0.28</td>
<td>4.15 0.02</td>
<td>4.15 0.05</td>
</tr>
</tbody>
</table>

CAS, casein; SP, sardine proteins; HF, high fat.
* Statistical analysis was performed using the least significant difference test. The values were significantly different at P < 0.05.
† SP v. CAS (P < 0.05).
‡ SP-HF v. SP or CAS-HF v. CAS (P < 0.05).

CAS increased LDL-HDL1-cholesterol, HDL2- and HDL3-TAG by 43, 63 and 52%, respectively. In the SP-HF group, HDL3-cholesterol was increased by 42% compared with the SP group. In contrast, SP v. CAS combined with 5 or 30% lipids induced a decrease of VLDL-cholesterol, LDL-HDL1-cholesterol, VLDL-TAG, LDL-HDL1-TAG, HDL2-TAG and HDL2-TAG. Moreover, in the SP v. CAS groups, HDL2-cholesterol enhanced by 50%, whereas HDL3-cholesterol lowered by 37%.

Lecithin:cholesterol acyltransferase activity

In the CAS-HF v. CAS groups, serum LCAT activity (Table 6) and its substrate HDL3-PL were 9-46- and 1-29-fold higher, respectively, whereas there was no significant difference in acyl acceptor HDL2-UC. The reaction product HDL2-cholesteryl esters (CE) was 3-55-fold lower. In the SP-HF group, HDL3-PL was 2-13-fold higher and HDL2-CE was 6-31-fold lower than in the SP group. However, in the SP group compared with the CAS group, serum LCAT activity, apoA-I and HDL2-CE were 4-, 1-97- and 3-15-fold higher, respectively, whereas HDL3-PL and HDL2-UC were 1-8- and 1-61-fold lower, respectively. In SP-HF compared with CAS-HF, LCAT activity, apoA-I and HDL2-UC concentrations were lower and HDL2-CE values were higher.

Discussion

The aim of the current work was to investigate the effects of SP on hyperglycaemia, insulin resistance, lipid parameters and LCAT activity, in rats fed HFD, followed by a single intraperitoneal low-dose (35 mg/kg BW) injection of STZ.

In diabetic rats fed HFD with CAS, glycaemia increased significantly, compared with that of rats fed a diet with 5% lipids. In contrast, SP consumption significantly lowered glycaemia values in diabetic rats fed a 30 or 5% lipid diet, compared with CAS, from d7 of the experiment. These results are in agreement with those of other authors, who reported that fish protein consumption improved muscle sensitivity to insulin and increased glucose absorption in normoglycaemic rats. This phenomenon was also observed in obese rats, and in humans. The hypoglycaemic effect of SP could be attributed to the improvement of insulin action, by reducing glucose release from hepatocytes and stimulating glucose utilisation in peripheral tissue or increasing glycogenesis. Data reported that insulin:glucose ratio was lowered in subjects receiving cod protein, presenting smaller insulin excursion, when compared with those fed milk proteins. Furthermore, it was possible that SP-derived amino acids stimulated glucose uptake and utilisation in peripheral tissue. In this case, taurine is reported to control hyperglycaemia in alloxan-induced diabetic rats. As sardines are a much richer source of taurine, this may also explain why the SP rats displayed lower glucose, insulin and insulin resistance than the CAS-fed rats. In addition, oral administration of arginine to diabetic hamsters or intraperitoneal administration of arginine to rats with alloxan-induced diabetes reduced plasma glucose levels by up to 65%. The mechanism was that arginine could stimulate the insulin secretion by pancreatic β-cells. Given the high arginine content in SP, this could strengthen our results, as an increase in HOMA-β indicating improved insulin secretory capacity of pancreatic β-cells was observed in SP v. CAS regardless of the fat content in the diet. The available evidence suggested that the action of insulin and arginine involved the following mechanisms. First, both insulin and arginine stimulated nitric oxide (NO) production by endothelial cells, which would contribute to increase the blood flow and, therefore, glucose and amino acid uptake by skeletal muscle in vivo. Second, NO itself stimulated GLUT and oxidation by skeletal muscle. Third, physiological concentrations of NO might inhibit muscle proteolysis.

Rats fed HFD compared with a diet with 5% lipids showed a significant decrease in glucose tolerance, HOMA-β and increase of HOMA-IR value. Dietary fat modification leads to changed cell membrane fatty acid composition, and it is associated with impaired insulin binding by decreasing the number of insulin receptors and GLUT. In addition, intracellular post-receptor disorders of liver, muscle (increased storage of TAG) and adipose tissue were observed. However, SP v. CAS showed increasing glucose tolerance given by the lower HOMA-IR value. Madani et al. reported that SP decreased plasma insulin and insulin resistance. The improved insulin sensitivity observed with SP may be because of the amino acid composition. It was shown that taurine normalises glucose metabolism and attenuates hyperinsulinaemia in high-fructose-fed rats, in addition, taurine levels were increased in rats fed SP compared with CAS.
During diabetes mellitus, HbA1c amount is greater. Diabetic rats fed SP compared with the CAS group showed low HbA1c level. Mellouk et al.\textsuperscript{(12)} reported a significant decrease in serum glucose and HbA1c in STZ-induced diabetic rats fed SP as compared with those fed CAS. It has been suggested that amino acid composition of SP could be responsible for different effects on HbA1c. Indeed, authors have shown that administration of taurine and glycine to diabetic rats significantly lowered the glucose content and HbA1c value, compared with untreated diabetic rats.\textsuperscript{(20)}

In addition, elevated biomarker enzymes, such as ALT and AST, were observed in diabetic rats, indicating liver damage induced by HFD. In contrast, SP showed a significant decrease in serum AST and ALT levels, indicating restored hepatic damage induced by diabetes. Thus, SP seem to have protective effects on the liver of diabetic rats.

Hyperlipidaemia has been reported to accompany hyperglycaemia state. Moreover, consumption of HFD is well known to cause increased chylomicron synthesis and absorption, which leads to increased TC and TAG levels, as well as endogenous VLDL production.\textsuperscript{(29)} In addition, increased hydroxy-methylglutaryl-CoA reductase and decreased lipoprotein lipase activities were attributed to HFD inducing dyslipidaemia.\textsuperscript{(30)}

In serum and liver, TC concentrations were higher with HFD, compared with the diet with 5% fats. In contrast, SP consumption induced a hypocholesterolaemic effect, regardless of lipid amounts in the diet (30 or 5% lipids). Indeed, in animals, dietary fish proteins reduced plasma cholesterol concentrations better than CAS.\textsuperscript{(11,12)} The hypocholesterolaemic response to SP may be ascribed to a decreased activity of cholesterol biosynthesis enzymes, as liver cholesterol content was low. This was consistent with the greater faecal lipids and cholesterol excretion. This mechanism could be because of increased bile acid synthesis, as reported by Lieset \textit{et al.}\textsuperscript{(31)}, who demonstrated that fish protein hydrolysates, rich in taurine and glycine, increased plasma bile acids levels concomitantly with reduced liver lipids. Furthermore, SP amino acid composition compared with CAS was different. Thus, in our previous study, fish proteins showed more arginine than CAS (6.5 vs. 3.6 g/100 g proteins, respectively), and low lysine:arginine ratio was lower in SP vs. CAS (1.07 vs. 2.05, respectively)\textsuperscript{(32)}. Low lysine:arginine ratio\textsuperscript{(33)} and specific amino acid content, such as taurine, methionine, cysteine and glycine\textsuperscript{(34)}, might be responsible for this effect. In addition, taurine lowered TAG and TC levels in diabetic rats, but this was because of activated 7α-hydroxylase, which participates in biliary acid synthesis\textsuperscript{(35)}. HFD feeding diabetic rats showed low HbA1c level. During diabetes mellitus, Advanced glycation end products impair lipid metabolism by diminishing the expression of ABCA-1, ABCG-1 and the activity of LCAT. ABCG-1 has a major role in the efflux of 7-ketocholesterol to large HDL minimising its apoptotic effects in macrophages\textsuperscript{(40)}. Thus, it could be interesting to clarify the mechanisms implicated in the reverse cholesterol transport, particularly the ABCA or ABCG transport proteins role in this diabetes type.

In conclusion, the present study suggests that an HFD, in diabetic rats, induces insulin resistance, hyperglycaemia and hyperlipidaemia. SP administration exerts an antihyperglycaemic effect and increases glucose tolerance. Moreover, SP have a hypocholesterolaemic effect by increasing faecal cholesterol excretion and hypotriglyceridaemic effect by decreasing liver synthesis of TAG. SP stimulate cholesterol efflux by enhancing LCAT activity. These effects seem to be more effective in diabetic rats fed a diet with 5% lipids. Thus, SP may be considered as an applicable approach in preventing or treating diabetes and its associated complications.

**Acknowledgements**

This research was supported by the General Directorate for Scientific Research and Technological Development of the Ministry of Higher Education and Scientific Research. N. B.: experimental study, sample collection, data interpretation and manuscript writing; F. Z. L.: experimental study and sample collection; M. B.: conception of the study, data interpretation and manuscript writing; F. O. B.: conception of the study, data analysis and interpretation, and manuscript writing.

The authors have no conflicts of interest regarding this article.
References


